Effects of vitamin D supplementation on depressive symptoms in type 2 diabetes mellitus patients: Randomized placebo-controlled double-blind clinical trial.
Biomarkers
/ analysis
Blood Glucose
/ analysis
Depressive Disorder, Major
/ etiology
Diabetes Mellitus, Type 2
/ complications
Dietary Supplements
Double-Blind Method
Female
Follow-Up Studies
Humans
Male
Middle Aged
Prognosis
Vitamin D
/ administration & dosage
Vitamin D Deficiency
/ physiopathology
Vitamins
/ administration & dosage
Depression
Diabetes
Randomized controlled trial
Vitamin D
Journal
Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250
Informations de publication
Date de publication:
Historique:
received:
14
05
2019
accepted:
10
06
2019
entrez:
14
8
2019
pubmed:
14
8
2019
medline:
25
1
2020
Statut:
ppublish
Résumé
Diabetes increases the odds of depression and depression is often associated with poor glycemic control and complications of diabetes. Vitamin D is also believed to improve glycemic control and ameliorate depressive symptoms. Therefore, we examined effects of vitamin D monotherapy (without antidepressant drugs) on depressive symptoms in Type 2 diabetic patients with mild to moderate depressive symptoms. We conducted 12 weeks, placebo-controlled, double-blind, randomized trial on 68 subjects with T2DM and mild to moderate depressive symptoms. Subjects received 100 μg (4000 IU) vitamin D (n = 32) or placebo (n = 34) daily. Beck Depression Inventory-II (BDI-II-PERSIAN) was applied for assessment of the severity of depression. Depression scores and metabolic profiles were measured at the beginning and end of trail. after 3 months of vitamin D supplementation, mean values of 25(OH) D increased from 15.5 ± 8.8 to 32.2 ± 8.9 ng/ml (p-value <0.001) in the vitamin D group. Moreover, BDI-II scores decreased from 15.2 ± 9.6 to 9.8 ± 7.2 (p-value <0.001) in the vitamin D group and 15.5 ± 11.2 to 13.7 ± 11.5 (p-value = 0.03) in placebo group. This decrease in BDI-II scores were significant (27.6% vs 10.8%) compared with placebo (p-value = 0.02). In term of metabolic profiles, mean change in level of Hemoglobin A1c (HbA1c), insulin and triglycerides (TG) were significantly higher in response to the treatment with vitamin D compared to placebo (p-value <0.02). In conclusion, supplementation of vitamin D in T2DM patients may protect these patients against the onset of major depressive disorder (MDD), with noticeable favorable effects on measures of metabolic profiles. NCT03008057.
Identifiants
pubmed: 31405646
pii: S1871-4021(19)30323-6
doi: 10.1016/j.dsx.2019.06.011
pii:
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Vitamins
0
Vitamin D
1406-16-2
Banques de données
ClinicalTrials.gov
['NCT03008057']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2375-2380Informations de copyright
Copyright © 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.